Introduction {#Sec1}
============

Hilar cholangiocarcinoma (HCCA) comprising approximately 50% of all malignant bile duct tumors, is an intractable cancer \[[@CR1]\], which requires a high level of expertise in hepatobiliary surgery due to the deep anatomical location of tumor \[[@CR2], [@CR3]\]. In addition, curative resection for HCCA is a complex procedure involving hepatectomy, lymphadenectomy, vascular resection and reconstruction, even pancreaticoduodenectomy (PD) \[[@CR4], [@CR5]\]. Consequently, curative resection is a challenging surgery and carries with a considerable risk of mortality and severe postoperative morbidity \[[@CR6], [@CR7]\]. Undoubtedly, curative resection offers HCCA patients the only potential chance for long-term survival, but the rates of mortality and morbidity require further improvement \[[@CR8]\]. Meanwhile, many definitive prognostic factors affecting the postoperative survival have not been identified and accepted by surgeons \[[@CR9]--[@CR13]\], despite majority investigations have focused on this field. Therefore, the aims of this study were to assess the surgical management for HCCA and analyze potential factors influencing postoperative prognosis.

Materials and Methods {#Sec2}
=====================

Patients {#Sec3}
--------

Between January 2006 and December 2014, 216 patients with a presumed diagnosis of HCCA were admitted to the Department of Hepatobiliary, Sun-Yat-Sen Memorial Hospital, Sun-Yat-Sen University. With the approval of local institutional review board, we reviewed the medical records of all potential candidates for surgery. Seventy-four patients without any surgical interventions were excluded due to multiple metastasis, severe preoperative malnutrition, compromised liver function or severe involvement of contralateral major vessels. Therefore, curative-intent laparotomy was conducted in the remaining 142 patients. Consequently, 95 patients underwent curative resection (R0 resection) and 47 patients were performed with palliative resection (R1 = 20, R2 = 27). All the 142 patients were enrolled into this study.

Preoperative Evaluation and Management {#Sec4}
--------------------------------------

To comprehensively evaluate disease lesion and assess surgical resectability, the laboratory and imaging examinations were carried out for all candidates. The lesion location, proximal and distal extension of tumor as well as vascular involvement extent were evaluated by ultrasonography, multidetector row computed tomography (MDCT), and magnetic resonance cholangiopancreatography (MRCP). Patients who were scheduled to accept major hepatectomy with preoperative serum total bilirubin over 11.70 mg/dL (200 μmol/L) were suggested with biliary drainage prior to surgery. None of patients underwent portal vein embolization (PVE). Percutaneous transhepatic cholangial drainage (PTCD) under ultrasound guidance was performed for 33 patients and 4 patients underwent endoscopic nasobiliary drainage (ENBD). When the surgical approach of extended hepatectomy was established preoperatively, three dimensional computed tomography (3-D CT) volumetry was applied to calculate the remnant liver in order to avoid hepatic failure postoperatively. Definitive surgery arrangement was carried out when preoperative serum total bilirubin level decreased to below 11.70 mg/dL (200 μmol/L), whereas those without biliary drainage were performed with surgery within 7 days.

Surgical Procedures {#Sec5}
-------------------

Surgical resections consisting of hemihepatectomy, extended hemihepatectomy, central hepatectomy, and external bile duct resection with or without caudate lobectomy were carried out on individuals referring to Bismuth-Corlette classification with imaging information. Locoregional lymphadenectomy including nodes at the hepatoduodenal ligament and upper part of the retropancreatic, and celiac nodes was routinely carried out. Upon the completion of the tumor resection, the biliary tract reconstruction was reestablished by Roux-en-Y bilioenteric anastomosis.

Vascular resection and reconstruction was carried out only when vessels adhered to and could not be freed from tumor entity during skeletonization of the hepatoduodenal ligament, regardless of whether the macrovascular invasion was detected preoperatively by MDCT \[[@CR14]\]. Meanwhile, the end-to-end anastomosis model or vascular prothesis was employed to reestablish vascular continuity.

Pathologic verification was performed for all resected specimens. R0 resection was of microscopically tumor-free and a microscopically positive margin was defined as R1 resection. R2 resection meant grossly positive margins. According to the predominant pathologic grade of differentiation, tumor was mainly classified as three types: well-differentiated, moderately differentiated, and poorly differentiated adenocarcinoma. Apart from these, perineural invasion, lymph nodal metastasis, vascular invasion including hepatic artery, portal vein, and tumor thrombi were also assessed.

Definition of Mortality and Morbidity {#Sec6}
-------------------------------------

Mortality was defined as any postoperative death occurring in-hospital stay. Major complications were regarded as having a grade of III--IV according to Clavien-Dindo classification \[[@CR15]\].

Statistics {#Sec7}
----------

Continuous variables were expressed as median and range. The category variables were expressed as numbers. Cumulative survival time counted from the month of surgery was calculated with the Kaplan-Meier method and difference in survival curves was compared through log-rank test. A Student's *t* test (two-tailed) or Mann--Whitney *U* tests and *χ* ^2^ test or Fisher's exact test were used to analyze continuous or categorical variables, respectively. A multivariate Cox proportional hazards regression analysis (enter method) was performed to identify variables with *P* values less than 0.05 in the univariate analysis. *P* values less than 0.05 was considered to be significant. The statistical analyses were performed with SPSS 17.0.

Results {#Sec8}
=======

Demographic and Clinicopathological Features of Patients {#Sec9}
--------------------------------------------------------

The current study population consisted of 84 male and 58 female patients with a mean age of 59.5 years (range, 28--82 years). According to Bismuth-Corlette classification, 16 (11.27%) patients were with type I, 15 (10.56%) with type II, 17 (11.97%) with type IIIA, 38 (26.76%) with IIIB, and 56 (39.44%) with IV. Clinicopathological and demographic features of these candidates showed no significant difference factors between these with R0 resection and those with non-curative resection, except for perineural invasion ( *P* = 0.000) (Table [1](#Tab1){ref-type="table"}).Table 1Demographic and clinicopathological features of 142 HCCA patientsCurative resection groupPalliative resection group (R1/R2)*P* valueNumber of patients9547Age59.92 (28--82)59.11 (32--76)0.681GenderM = 57, F = 38M = 27, F = 200.771Mean serum total bilirubin219.05 (5.7--712.7)207.9(9.6--647.5)0.504CEA6.87 ( 0.4--202.9)16.3(0.5--352.9)0.176CA19-92376.3 (0--100,000)5820.5(0--100,000)0.228ALB37.95 (17.9--47.2)37.78( 28.2--45.8)0.531PTCD26110.688Bismuth-Corlette classification:0.122 I97 II87 IIIA98 IIIB317 IV3818Pathological differentiation:0.500 Well3316 Moderate3413 Poor2818Perineural invasion51100.000Lymph nodes metastases47220.765Hepatitis virus infection1240.465No.12 lymph nodes invasion^a^39160.420Tumor thrombi1940.080^a^Lymph nodes at hepatoduodenal ligament

Operative Variables {#Sec10}
-------------------

In the whole cohort, 95 patients were performed with R0 resection, while the remaining 47 underwent non-curative resection including R1 resection (*n* = 20) and R2 resection (*n* = 27). A total of 92 patients (92/142, 64.8%) underwent combined with hepatectomy. Meanwhile, 34 out of these 92 (37.0%) patients underwent caudate lobectomy. Consequently, the R0 resection rate of those who underwent combined with hepatectomy was 75% (69/92). In addition, another 2 patients with type I lesion were conducted with PD. The details of surgical procedures of candidates who underwent surgery were depicted in Table [2](#Tab2){ref-type="table"}.Table 2Sugical procedures of 142 HCCA patientsBismuth-Corlette classification:IIIIIIAIIIBIVNumbers1615173856Margin status: R09893138 R134616 R2432612Surgical procedures: External bile duct resection1213359 External bile duct resection with S4b21222 Right hemihepatectomy009013 Right hemihepatectomy with S100100 Extended right hemihepatectomy00205 Extended right hemihepatectomy with S100004 Left hemihepatectomy000119 Left hemihepatectomy with S1010157 Extended left hemihepatectomy with S100033 Central hepatectomy00024 Pancreaticoduodenectomy20000

Vascular resection and reconstruction was carried out in 19 patients including right hepatic artery alone (*n* = 6), portal bifurcation plus right hepatic artery (*n* = 3), and portal bifurcation alone (*n* = 10). The portal vein reconstruction was by model of end-to-end anastomosis (*n* = 12) and vascular prothesis (*n* = 1) between the residual trunk and corresponding branch, and the hepatic arterial reconstruction were based on fashion of end-to-end (*n* = 4) or with gastroduodenal artery anastomosis (*n* = 2 ).

Postoperative Hospital Stay and Survival {#Sec11}
----------------------------------------

The median postoperative hospital stay was 23 days (range 13--119 days) with curative resection and 14 days (8-105 days) with non-curative resection. The cumulative overall 1-year, 3-year, and 5-year survival rates were 76.3, 27.8, and 11.3%, respectively, in curative resection group vs 36.4, 10.8, and 0% in non-resection group (*P* = 0.000). Median survival time after curative resection was 22 and 10 months after non-curative resection.

Mortality and Morbidity {#Sec12}
-----------------------

The perioperative overall mortality rate in this study was 7.0% (10/142). Mortality occurred to 10 patients consisting of 4 in curative resection group and 6 in non-curative resection group. The main causes of mortality included hepatic failure resulting in multiple organ failure (*n* = 6), pneumonia causing respiratory failure (*n* = 2), postoperative gastrointestinal hemorrhage (*n* = 1), and anastomosis site leakage (*n* = 1). A total of 83 patients suffered from postoperative complications with the overall morbidity rate of 58.5%. Meanwhile, 27.5% patients (39/83) encountered major complications (grade III to IV). Bile leakage was the most frequent complication and observed in 38 patients. Relaparotomy was required in 6 patients due to intra-abdominal bleeding (*n* = 4) and bilioenteric anastomosis bleeding (*n* = 2) within 7 days postoperatively. The details of postoperative complications were summarized in Table [3](#Tab3){ref-type="table"}.Table 3Postoperative complications of 142 HCCA patientsNo. of patients with curative resection *n* = 95No. of patients with palliative resection *n* = 47Total *n* = 142Morbidity^a^ Grade IVa  Hepatic encephalopathy101  Hepatic or renal insufficiency437  ARDS202 Grade IIIb  Intra-abdominal abscess000  Liver abscess066  Bilioenteric anastomosis bleeding202  Intra-abdominal bleeding314 Grade IIIa  Intra-abdominal abscess202  Gastrointestinal bleeding9110  Pleural effusion13417  Ascites20222  Liver abscess011 Grade II  Bile leakage381149  Pneumonia15015  Pulmonary abscess101  Intra-abdomonial infection21526  Sepsis8210  Wound infection325 Grade I19928 No. of complications:1614720 No. of patients with complications632083 No. of patients with major complications291039 Postoperative hospital stays (day)2314^a^According to Clavein-Dindo classification

Statistic Analysis {#Sec13}
------------------

Univariate analysis suggested CA19--9, preoperative serum total bilirubin, marginal status, pathological differentiation, and lymph nodes status were significant predictors for poor survival (Table [4](#Tab4){ref-type="table"}). Meanwhile, Cox multivariate analysis disclosed that non-curative resection (RR: 2.414, 95% CI 1.586--3. 676, *P* = 0.000), pathological differentiation (*P* = 0.015), serum total bilirubin ≥10 mg/dL (RR: 1.844, 95% CI 1.235--2.752, *P* = 0.003) were independent prognostic factors (Fig. [1](#Fig1){ref-type="fig"}).Table 4Univariate and multivariate analysis of prognostic factors of survival outcome of 142 HCCA patientsFactorsNo.of patientsUnivariate analysisMultivariate analysisMedian survival (month)*χ* ^2^ value*P* valueRR (95% CI)*P* valueAge0.9750.332 \<607220 ≥607015Agender0.5210.471 Male8417 Female5814TBIL5.4360.0200.003 \<10 mg/dL7920Reference ≥10 mg/dL63141.844, 95% CI (1.235--2.752)CEA level3.6340.057 \<15 ng/ml13417 ≥15 ng/ml88CA-199 level4.7480.0290.459 \<200 U/ml6720Reference ≥200 U/ml75131.174, 95% CI (0.768--1.793)ALB level0.2920.589 \<35 g/L2518 ≥35 g/L11716PTCD0.7630.382 Present3714 Absent10517Bismuth-Corlette classification2.9930.559 I1620 II1512 IIIA1715 IIIB3817 IV5618Hepatitis virus infection0.3980.528 Present1616 absent12620Resection margin21.8580.0000.000 R09522Reference R1/R247102.268, 95% CI (1.493--3.444)Combined hepatectomy0.3020.583 Yes9217 No5016Combined caudate lobectomy1.1210.271 Present3422 Absent10815Combined vascular reconstruction0.1230.726 Present1917 Absent12316Postoperative chemotherapy1.3310.249 Yes5420 No8814Pathologic differentiation11.3010.0040.015 Well4924Reference Moderate47141.139, 95% CI (0.785--2.217) Poor46122.405, 95% CI (1.250--3.345)Perineural invasion1.1870.276 Present6318 Absent7915Tumor thrombi0.7760.378 Present1916 Absent12317Lymph node metastases4.5010.0340.247 Present69201.280, 95% CI (0.843--1.945) Absent7315ReferenceNo.12 lymph node invasion3.5780.059 Present9017 Absent5214 Fig. 1Overall survival rates according to the status of resection margin (*P* = 0.000), preoperative serum total bilirubin level (*P* = 0.020), and pathological differentiations (*P* = 0.004). Cox multivariate analysis revealed that non-curative resection (RR: 2.414, 95% CI 1.586--3.676, *P* = 0.000), preoperative serum total bilirubin above 10 mg/dL (RR: 1.844, 95%CI 1.235--2.752, *P* = 0.003) and pathological differentiation (*P* = 0.015) were independent prognostic risk factors for poor survival

Discussion {#Sec14}
==========

Surgical resection has been recognized as an only potential curative option for HCCA \[[@CR1], [@CR2]\]. Despite close proximity to hilum vital structures and longitudinal extension of HCCA make curative resection a challenge, an improvement in postoperative survival has been reported with the advances of surgical techniques. The recent literature reviews of high-volume center of HCCA treated surgically indicate the median survival time is 16--40 months with 5-year survival rate of 11--40%, and perioperative mortality rate is around 10% with morbidity rate of approximate 42--75% \[[@CR2], [@CR4], [@CR9], [@CR13], [@CR16], [@CR17]\]. In the present study, combined hepatectomy including caudate lobectomy was conducted in 64.8% patients (92/142), and 13.39% patients (19/142) underwent concomitant vascular resection and reconstruction. Besides that, it was noted that 66.20% patients (94/142) who underwent surgical resection were with type III (IIIA or IIIB) or type IV lesion. Consequently, the one-year, three-year, and five-year survival rates in curative resection group were 76.3, 27.8, and 11.3%, respectively, and overall morbidity rate was 58.3% with perioperative mortality of 7.0%. Despite our results was not enough favorable but acceptable, at least, which was compatible with that reported in previous published series.

It is an incontrovertible fact combined hepatectomy or extended hepatectomy have markedly increased the resectable rate of HCCA \[[@CR6], [@CR18], [@CR19]\]. It has been increased from traditionally 30% to currently 49.2--95% \[[@CR2], [@CR9], [@CR13]\]. Simultaneously, the median survival of HCCA has also been dramatically ameliorated. KY. Paik et al. \[[@CR20]\] reported 5-year survival rate was 64.2% without any in-hospital death of 16 patients who underwent right trisectionectomy with caudate lobectomy. In the study of Shimizu et al. \[[@CR21]\], the R0 rate was 63.6% for patients who underwent left-side hepatectomy and 5-year survival was 36.7% with median survival of 24.4 months. In addition, patients with type IV lesion were previously considered not suitable for surgery, which was documented by the American Joint Committee on Cancer (AJCC) cancer staging manual (7th, edition). However, a study of combined extended hepatectomy for those who with type IV from Jang et al. \[[@CR22]\] indicated that median survival time was 16 months in curative resection group and 12 months in palliative resection group (*P* = 0.006). Consistent with the previous literatures, R0 resection rate of those who underwent combined with hepatectomy was 75% (69/92) in this series, which was higher than the overall curative resection rate of 66.9% (95/142). Furthermore, 67.86% (38/56) patients with type IV underwent curative resection with median survival time of 23 months, which was significantly better than that of 7 months with non-curative resection (*P* = 0.000). Although combined hepatectomy did not develop impacts on postoperative survival in our study (*P* = 0.302), we believed that combined hepatectomy was essential to obtain higher R0 resection rate and benefit selected HCCA patients.

For another, combined with vascular resection and reconstruction has also made contribution to improvement resectability of HCCA currently, though it was regarded as a common surgical contraindication previously \[[@CR23], [@CR24]\]. The 5 year survival rate of combined with portal vein resection and reconstruction for HCCA in series of over 10 cases reported ranges from 9.9% to 25% with mortality of 9.6%--40% \[[@CR25], [@CR26]\]. In the current series, the median survival time for 19 patients who underwent combined with vascular resection and reconstruction was 17 months with one-year, three-year survival rates of 78.8%, 21.3% respectively. And the mortality was 5.26% (1/19). Although these outcomes was inferior to results in recent literatures, compared with median survival of advanced cholangiocarcinoma without any interventional procedures, combined with vascular resection and reconstruction offered advanced HCCA patients chance for acceptable survival benefits to some extent \[[@CR27], [@CR28]\].

As we all know, postoperative liver failure is the fatal complication of aggressive hepatic surgery, which makes the significance of preoperative biliary drainage under controversial debate to certain extent. Although zero mortality rate after R0 resection for HCCA has been achieved by Sano et al. with preoperative biliary drainage routinely applied \[[@CR13]\], multivariate analysis of their study also revealed preoperative cholangitis was associated with postoperative mortality and morbidity. In this study, patients who were scheduled to undergo major hepatectomy with preoperative serum total bilirubin over 11.70 mg/dL (200 μmol/L) were suggested with biliary drainage prior to surgery. Consequently, patients with preoperative serum total bilirubin below 10 mg/dL obtained apparent survival benefits than those with that above 10 mg/dL (20 vs 14 months, *P* = 0.003). Additionally, preoperative biliary drainage trends to result in bile duct infections, even delay treatment \[[@CR29]\]. Therefore, to obtain the better outcomes of surgery, preoperative biliary drainage should be a selective procedure which is depended on preoperative definitive serum total bilirubin level and scheduled surgical policy.

Although many investigations published have established various clinicopathologic factors focusing on affecting prognosis of HCCA \[[@CR9]--[@CR13], [@CR23]\], the most consistently reported and well-recognized independently determinant factors is surgical margin status. Hepatitis and tumor thrombi regarded as potential prognostic factors were seldom discussed. To our knowledge, only a few studies have described the role of hepatitis virus infection for HCCA. In the study of Abdel Wahab M et al. \[[@CR30]\], the median survival of patients with HCV infection was shorter than that of non-hepatitis virus infection patients (*P* = 0.005) and multivariate analysis confirmed that it was an independent prognostic factor. On the contrary, we failed to note that viral infection such as HBVor HCV has negative effect on postoperative prognosis of HCCA (16 vs 20 months, *P* = 0.528). Perhaps, the low morbidity of hepatitis (16/142) in this study was accounted for this discrepancy. Of course, the significance of hepatitis viral infection has remained uncertain and should be further explored. As for tumor thrombi, few reports concerned can be traced in recent literatures. In this study, the pathological examination revealed 19 patients with tumor thrombi invasion. As a result, the median survival time with pathological tumor thrombi invasion was 16 months, comparing with 17 months in absence of tumor thrombi invasion (*P* = 0.378). With the limitation of small sample, we could not confirm that whether the poor survival was associated with tumor thrombi invasion. Even so, tumor thrombi as an interesting factor deserves further exploration.

There are some limitations in this retrospective study. First, our relatively small study cohort resulting in influencing factors was not perceived as statistically reasonable or convincing. Second, in light of the retrospective nature of most published series including the current one, more valid data about surgical approach for HCCA should be provided by the future multicenter prospective studies. Last but not the least, the significance of postoperative adjuvant chemotherapy remains to be elaborated by randomized controlled trials, though our study did not demonstrate effects of adjuvant chemotherapy due to the small sample.

In summary, curative resection as a single curative therapy has benefited HCCA patients with acceptable mortality and morbidity. Combined hepatectomy with vascular resection and reconstruction have improved the resectability rate and survival outcomes. The further refinements of aggressive surgical techniques and improvement of therapeutic strategy would benefit more advanced HCCA patients.
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